{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T09:53:37Z","timestamp":1774864417219,"version":"3.50.1"},"update-to":[{"DOI":"10.12688\/f1000research.21962.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000}}],"reference-count":27,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns3:p>Gabapentin and pregabalin, commonly known as gabapentinoids, have been widely used globally. This paper highlights the serious breathing problems due to using gabapentin and pregabalin which was warned by the United States Food and Drug Administration on December, 2019. In this article, we tried to recommend suggestions for controlling these adverse drug reactions (ADRs). Safety reports of gabapentin and pregabalin should be obtained from concerned manufacturers and reviewed for respiratory depression effects. There should be strict prescription monitoring and drug use evaluation studies. Concurrent use of gabapentin and pregabalin with other respiratory depressants such as opioids should be strictly monitored. Educating patients can help in the early detection of ADRs due to gabapentin and pregabalin. Anecdotal reports on these medications should be encouraged.<\/ns3:p>","DOI":"10.12688\/f1000research.21962.2","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T09:13:56Z","timestamp":1614244436000},"page":"32","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Respiratory concerns of gabapentin and pregabalin: What does it mean to the pharmacovigilance systems in developing countries?"],"prefix":"10.12688","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-7120","authenticated-orcid":false,"given":"Sunil","family":"Shrestha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-3940","authenticated-orcid":false,"given":"Subish","family":"Palaian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"13-21","DOI":"10.2147\/JEP.S124391","article-title":"Review about gabapentin misuse, interactions, contraindications and side effects.","volume":"9","author":"G Quintero","year":"2017","journal-title":"J Exp Pharmacol."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0140-6736(13)60338-4","article-title":"Gabapentin for refractory chronic cough.","volume":"381","author":"K Inoue","year":"2013","journal-title":"Lancet."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"26-48","DOI":"10.1016\/j.clinthera.2007.01.013","article-title":"Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders.","volume":"29","author":"D Tassone","year":"2007","journal-title":"Clin Ther."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"55-62","DOI":"10.1007\/s40264-012-0006-6","article-title":"Adverse drug reactions to gabapentin and pregabalin: a review of the French pharmacovigilance database.","volume":"36","author":"R Fuzier","year":"2013","journal-title":"Drug Saf."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"38-56","DOI":"10.1177\/2042098613505614","article-title":"Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain.","volume":"5","author":"C Toth","year":"2014","journal-title":"Ther Adv Drug Saf."},{"key":"ref-6","article-title":"Gabapentin and the risk of respiratory depression without concomitant opioids.","year":"2017"},{"key":"ref-7","article-title":"Potential Signals of Serious Risks\/New Safety Information Identified from the FDA Adverse Event Reporting System (FAERS).","year":"2019"},{"key":"ref-8","article-title":"US flags two top neurological drugs used in India, warns of serious breathing difficulties.","year":"2019"},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"758-763","DOI":"10.1007\/s11096-017-0570-z","article-title":"Pharmacovigilance in developing countries (part I): importance and challenges.","volume":"40","author":"S Elshafie","year":"2018","journal-title":"Int J Clin Pharm."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"S7-S19","DOI":"10.4103\/0976-500X.120941","article-title":"Pharmacovigilance in Asia.","volume":"4","author":"P Biswas","year":"2013","journal-title":"J Pharmacol Pharmacother."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"e010912","DOI":"10.1136\/bmjopen-2015-010912","article-title":"Cross-sectional study exploring barriers to adverse drug reactions reporting in community pharmacy settings in Dhaka, Bangladesh.","volume":"6","author":"M Amin","year":"2016","journal-title":"BMJ Open."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"102-108","DOI":"10.1002\/cpt.346","article-title":"Assessment of the impact of scheduled postmarketing safety summary analyses on regulatory actions.","volume":"100","author":"S Sekine","year":"2016","journal-title":"Clin Pharmacol Ther."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"817-21","DOI":"10.1016\/s0006-2952(02)00842-0","article-title":"Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.","volume":"63","author":"D Mukherjee","year":"2002","journal-title":"Biochem Pharmacol."},{"key":"ref-14","first-page":"41-5","article-title":"Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States.","author":"M Saito","year":"2005","journal-title":"Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S0140-6736(07)61485-8","article-title":"Ensuring drug safety: lessons from the thiazolidinediones.","volume":"370","year":"2007","journal-title":"Lancet."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40545-019-0173-2","article-title":"Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone.","volume":"12","author":"O Abiri","year":"2019","journal-title":"J Pharm Policy Pract."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"S33-S37","DOI":"10.4103\/0976-500X.120945","article-title":"Pharmacovigilance in pharmaceutical companies: An overview.","volume":"4","author":"M Mamm\u00ec","year":"2013","journal-title":"J Pharmacol Pharmacother."},{"key":"ref-18","article-title":"Pharmacovigilance: the role of pharmaceutical companies to protect patients from adverse drug reactions","author":"S Nukala","year":"2017"},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"1363-1369","DOI":"10.1001\/archinte.165.12.1363","article-title":"Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.","volume":"165","author":"D Wysowski","year":"2005","journal-title":"Arch Intern Med."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"561-575","DOI":"10.1007\/s40264-016-0409-x","article-title":"A pharmacovigilance signaling system based on FDA regulatory action and post-marketing adverse event reports.","volume":"39","author":"K Hoffman","year":"2016","journal-title":"Drug Saf."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12916-016-0553-2","article-title":"Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.","volume":"14","author":"I Onakpoya","year":"2016","journal-title":"BMC Med."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"292-294","DOI":"10.1001\/jamainternmed.2017.7856","article-title":"Gabapentinoid Use in the United States 2002 Through 2015.","volume":"178","author":"M Johansen","year":"2018","journal-title":"JAMA Intern Med."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"e65-e67","DOI":"10.1097\/SLA.0000000000003317","article-title":"Association \u2018Between Gabapentinoids on the Day of Colorectal Surgery and Adverse Postoperative Respiratory Outcomes.","volume":"270","author":"T Ohnuma","year":"2019","journal-title":"Ann Surg."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"221-229","DOI":"10.2106\/JBJS.19.00889","article-title":"Dose-Dependent Association of Gabapentinoids with Pulmonary Complications After Total Hip and Knee Arthroplasties.","volume":"102","author":"T Ohnuma","year":"2020","journal-title":"J Bone Joint Surg Am."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3389\/fphar.2016.00090","article-title":"Patient Participation and the Use of Ehealth Tools for Pharmacoviligance.","volume":"7","author":"J Berrewaerts","year":"2016","journal-title":"Front Pharmacol."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"1272-83","DOI":"10.2146\/ajhp080086","article-title":"ASHP guidelines on the pharmacy and therapeutics committee and the formulary system.","volume":"65","author":"L Tyler","year":"2008","journal-title":"Am J Health Syst Pharm."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"113-135","DOI":"10.1007\/s41060-019-00175-3","article-title":"Harnessing social media data for pharmacovigilance: a review of current state of the art, challenges and future directions.","volume":"8","author":"D Pappa","year":"2019","journal-title":"Int J Data Sci Anal."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/9-32\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-32\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-32\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T04:35:53Z","timestamp":1614314153000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/9-32\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":27,"URL":"https:\/\/doi.org\/10.12688\/f1000research.21962.2","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.54542.r80176","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.54542.r80176","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/9-32\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.24217.r67201, Sue E Jordan, College of Human and Health Sciences, Swansea University, Swansea, UK, 31 Jul 2020, version 1, 1 approved, 1 approved with reservations","URL":"https:\/\/f1000research.com\/articles\/9-32\/v1#referee-response-67201","order":0,"name":"referee-response-67201","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.54542.r80176, Tetsu Ohnuma, Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina, USA, 26 Feb 2021, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/9-32\/v2#referee-response-80176","order":1,"name":"referee-response-80176","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}